poisar

Stocks · News reference

Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy

BenzingaBenzinga Newsdesk

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    Scholar Rock Holding Q3 2026 Earnings Call Transcript

    Scholar Rock Holding (NASDAQ:SRRK) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga

  2. SEC EDGARSEC EDGAR

    8-K filing — Scholar Rock Holding Corp (SRRK)

    Filed: 2026-11-10 AccNo: 0001193125-26-454423 Size: 11 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure